Skip to content

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02710097
Acronym
THC-ETOH-II
Enrollment
40
Registered
2016-03-16
Start date
2016-03-01
Completion date
2026-12-01
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Effect, Cannabis, Driving Under the Influence of Alcohol and Other Drugs

Brief summary

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

Detailed description

To study the effects of oral ethanol (target BAC of \ 0.04g/dl; equivalent to consuming approximately 2 drinks over 1 hour) and vaporized cannabis (\ 450 mg cannabis plant material at a THC concentration of \ 1.7%; roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or "joint") on driving.

Interventions

\~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or "joint". Administered over 20 minutes via a vaporizer.

DRUGPlacebo

Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.

0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Males or females 21 to 55 years of age (extremes included). * Occasional current cannabis users. * Experience with drinking 2 or more standard drinks of alcohol at least once in lifetime. * Able to provide informed consent.

Exclusion criteria

* Cannabis naïve. * Alcohol naïve. * Positive pregnancy screen * Hearing deficits.

Design outcomes

Primary

MeasureTime frame
Road Tracking Errorbaseline, +20, +50, +120, +180 mins after start of alcohol administration

Secondary

MeasureTime frameDescription
Biphasic Alcohol Effects Scale (BAES)baseline, +20, +50, +120, +180, +240 mins after start of alcohol administrationA scale designed to assess the stimulant and sedative effects associated with alcohol intoxication
Visual Analog Scale (VAS)baseline, +20, +50, +120, +180, +240 mins after start of alcohol administrationFeeling states associated with alcohol and cannabis intoxication will be measured using this self-report scale of feeling states.
Cognitive Test Battery+40 mins after start of alcohol administrationSeveral computer tasks will be administered to assess alcohol and THC effects on driving related cognition, including: visual vigilance, visual motor function, attention and working memory, and processing speed.
Willingness to Drive Scalebaseline, +20, +50, +120, +180, +240 mins after start of alcohol administrationSubjects will be asked to rate their willingness to drive at their current state in the context of various scenarios including willingness to drive from testing facility to a number of destinations that are different driving distances.
Number of Joints Scalebaseline, +20, +50, +120, +180, +240 mins after start of alcohol administrationSubjects will be asked to rate the number of standard joints that they believe they have been administered.
Number of Drinks Scalebaseline, +20, +50, +120, +180, +240 mins after start of alcohol administrationSubjects will be asked to rate the number of standard drinks that they believe they have been administered.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026